IMD-0354

CAT: 0804-HY-10172-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10172-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity[1]. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC50 of 1.2 uM[2].
CAS Number
[978-62-1]
Product Name Alternative
IKK2 Inhibitor V
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
IKK
Type
Reference compound
Related Pathways
NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/IMD-0354.html
Purity
99.46
Solubility
DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=CC(Cl)=CC=C2O
Molecular Formula
C15H8ClF6NO2
Molecular Weight
383.67
Precautions
H302, H315, H319, H335
References & Citations
[1]Tanaka A, et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood. 2005 Mar 15;105 (6) :2324-31.|[2]Li YR, et al. Study of the inhibitory effects on TNF-α-induced NF-κB activation of IMD0354 analogs. Chem Biol Drug Des. 2017 Dec;90 (6) :1307-1311.|[3]Tanaka A, et al. A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res. 2006 Jan 1;66 (1) :419-26.|[4]Lennikov A, et al. Amelioration of endotoxin-induced uveitis treated with an IκB kinase β inhibitor in rats. Mol Vis. 2012;18:2586-97.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
IKK-β

Popular Products